Daylight photodynamic therapy with methyl aminolevulinate cream is as effective as conventional photodynamic therapy with blue light in the treatment of actinic keratosis: a controlled randomized intra‐individual study
Background We know the efficacy of daylight phototherapy dynamic (DL‐PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with red light using methyl aminolevulinate cream and not with blue light. PDT with blue light is another conventional PDT that is effec...
Saved in:
Published in | Journal of the European Academy of Dermatology and Venereology Vol. 34; no. 8; pp. 1730 - 1735 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.08.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background
We know the efficacy of daylight phototherapy dynamic (DL‐PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with red light using methyl aminolevulinate cream and not with blue light. PDT with blue light is another conventional PDT that is effective in the treatment of AKs.
Objectives
The aim of this study is to assess the efficacy and the safety of DL‐PDT vs. PDT in blue light in the treatment of AKs.
Methods
This randomized, controlled, intra‐individual efficacy and safety study enrolled 26 subjects. AKs on the face/scalp were treated once, with DL‐PDT on one side and c‐PDT on the contralateral side. Primary endpoints for DL‐PDT at week 12 were efficacy with clearance of AKs and safety with assessment of pain. Lesions with complete response 12 weeks after one treatment session were followed until week 24.
Results
More than 1000 AK were studied. At week 12, the raw number of disappeared AK lesions at 3‐month follow‐up was 19.6 (±6.0) for DL‐PDT and 20.0 (±6.9) for c‐PDT with P = 0.8460 (90.5% vs. 94.2% of AK disappearance, respectively). The response was maintained at 6 months (90.0% and 94.6% of AK reduction, respectively). DL‐PDT was nearly painless than c‐PDT with light blue: 1.2 vs. 5.1, respectively (P < 0.0001).
Conclusions
Daylight‐PDT seems as effective as c‐PDT with light blue and DL‐PDT is less painful. The response of DL‐PDT was sustainable until 6 months. |
---|---|
AbstractList | We know the efficacy of daylight phototherapy dynamic (DL-PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with red light using methyl aminolevulinate cream and not with blue light. PDT with blue light is another conventional PDT that is effective in the treatment of AKs.BACKGROUNDWe know the efficacy of daylight phototherapy dynamic (DL-PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with red light using methyl aminolevulinate cream and not with blue light. PDT with blue light is another conventional PDT that is effective in the treatment of AKs.The aim of this study is to assess the efficacy and the safety of DL-PDT vs. PDT in blue light in the treatment of AKs.OBJECTIVESThe aim of this study is to assess the efficacy and the safety of DL-PDT vs. PDT in blue light in the treatment of AKs.This randomized, controlled, intra-individual efficacy and safety study enrolled 26 subjects. AKs on the face/scalp were treated once, with DL-PDT on one side and c-PDT on the contralateral side. Primary endpoints for DL-PDT at week 12 were efficacy with clearance of AKs and safety with assessment of pain. Lesions with complete response 12 weeks after one treatment session were followed until week 24.METHODSThis randomized, controlled, intra-individual efficacy and safety study enrolled 26 subjects. AKs on the face/scalp were treated once, with DL-PDT on one side and c-PDT on the contralateral side. Primary endpoints for DL-PDT at week 12 were efficacy with clearance of AKs and safety with assessment of pain. Lesions with complete response 12 weeks after one treatment session were followed until week 24.More than 1000 AK were studied. At week 12, the raw number of disappeared AK lesions at 3-month follow-up was 19.6 (±6.0) for DL-PDT and 20.0 (±6.9) for c-PDT with P = 0.8460 (90.5% vs. 94.2% of AK disappearance, respectively). The response was maintained at 6 months (90.0% and 94.6% of AK reduction, respectively). DL-PDT was nearly painless than c-PDT with light blue: 1.2 vs. 5.1, respectively (P < 0.0001).RESULTSMore than 1000 AK were studied. At week 12, the raw number of disappeared AK lesions at 3-month follow-up was 19.6 (±6.0) for DL-PDT and 20.0 (±6.9) for c-PDT with P = 0.8460 (90.5% vs. 94.2% of AK disappearance, respectively). The response was maintained at 6 months (90.0% and 94.6% of AK reduction, respectively). DL-PDT was nearly painless than c-PDT with light blue: 1.2 vs. 5.1, respectively (P < 0.0001).Daylight-PDT seems as effective as c-PDT with light blue and DL-PDT is less painful. The response of DL-PDT was sustainable until 6 months.CONCLUSIONSDaylight-PDT seems as effective as c-PDT with light blue and DL-PDT is less painful. The response of DL-PDT was sustainable until 6 months. We know the efficacy of daylight phototherapy dynamic (DL-PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with red light using methyl aminolevulinate cream and not with blue light. PDT with blue light is another conventional PDT that is effective in the treatment of AKs. The aim of this study is to assess the efficacy and the safety of DL-PDT vs. PDT in blue light in the treatment of AKs. This randomized, controlled, intra-individual efficacy and safety study enrolled 26 subjects. AKs on the face/scalp were treated once, with DL-PDT on one side and c-PDT on the contralateral side. Primary endpoints for DL-PDT at week 12 were efficacy with clearance of AKs and safety with assessment of pain. Lesions with complete response 12 weeks after one treatment session were followed until week 24. More than 1000 AK were studied. At week 12, the raw number of disappeared AK lesions at 3-month follow-up was 19.6 (±6.0) for DL-PDT and 20.0 (±6.9) for c-PDT with P = 0.8460 (90.5% vs. 94.2% of AK disappearance, respectively). The response was maintained at 6 months (90.0% and 94.6% of AK reduction, respectively). DL-PDT was nearly painless than c-PDT with light blue: 1.2 vs. 5.1, respectively (P < 0.0001). Daylight-PDT seems as effective as c-PDT with light blue and DL-PDT is less painful. The response of DL-PDT was sustainable until 6 months. Background We know the efficacy of daylight phototherapy dynamic (DL‐PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with red light using methyl aminolevulinate cream and not with blue light. PDT with blue light is another conventional PDT that is effective in the treatment of AKs. Objectives The aim of this study is to assess the efficacy and the safety of DL‐PDT vs. PDT in blue light in the treatment of AKs. Methods This randomized, controlled, intra‐individual efficacy and safety study enrolled 26 subjects. AKs on the face/scalp were treated once, with DL‐PDT on one side and c‐PDT on the contralateral side. Primary endpoints for DL‐PDT at week 12 were efficacy with clearance of AKs and safety with assessment of pain. Lesions with complete response 12 weeks after one treatment session were followed until week 24. Results More than 1000 AK were studied. At week 12, the raw number of disappeared AK lesions at 3‐month follow‐up was 19.6 (±6.0) for DL‐PDT and 20.0 (±6.9) for c‐PDT with P = 0.8460 (90.5% vs. 94.2% of AK disappearance, respectively). The response was maintained at 6 months (90.0% and 94.6% of AK reduction, respectively). DL‐PDT was nearly painless than c‐PDT with light blue: 1.2 vs. 5.1, respectively (P < 0.0001). Conclusions Daylight‐PDT seems as effective as c‐PDT with light blue and DL‐PDT is less painful. The response of DL‐PDT was sustainable until 6 months. |
Author | Couraud, A. Labrunie, A. Bédane, C. Kerob, D. Assikar, S. |
Author_xml | – sequence: 1 givenname: S. orcidid: 0000-0003-1625-5203 surname: Assikar fullname: Assikar, S. email: safae.assikar@chu-limoges.fr organization: CHU Dupuytren – sequence: 2 givenname: A. surname: Labrunie fullname: Labrunie, A. organization: CHU Dupuytren – sequence: 3 givenname: D. surname: Kerob fullname: Kerob, D. organization: Galderma International – sequence: 4 givenname: A. surname: Couraud fullname: Couraud, A. organization: CHU Dupuytren – sequence: 5 givenname: C. surname: Bédane fullname: Bédane, C. organization: CHU Dupuytren |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31955461$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kbFu1TAUhi1URG8LAy-APNIhrR3HScyGWiigSizAGjn2MdfFsS-xkypMPAIPyNQnweEWBiTqxT4-3_8f6fxH6MAHDwg9peSU5nN2redTWpekfYA2tKrbgpGWHaANEWVdCMHFITqK8ZoQQilvH6FDRgXnVU036OeFXJz9vE14tw0p6MXLwSqctjDK3YJvbNriAdJ2cTg3fHAwT856mQCrEeSAbcQyYjAGVLIzrIUKfgafbPDS3WPbuwnwfrb1awun7JiGLMXBYJn9fNZ8yZIUoo0vsFyt0xicA41H6XUY7Lf8tPlT3n7_Yb22s9VTHhvTpJfH6KGRLsKTu_sYfXz96sP5m-Lq_eXb85dXhWIlbwtTaiIVlb2AilSSy1r0RIiqES0XjNSyNUaUhjfAm1ao2miu27KqmoYxxZueHaPne9_dGL5OEFM32KjAOekhTLErWVWyuqSEZ_TZHTr1A-huN9pBjkv3J5EMnOwBNYYYRzB_EUq6Ne0up939TjuzZ_-wyia5Lj7vw7r7FDfWwfJ_6-7dxae94hc8usLx |
CitedBy_id | crossref_primary_10_1016_j_dyepig_2024_112262 crossref_primary_10_3389_fchem_2021_691697 crossref_primary_10_1177_12034754241266177 crossref_primary_10_1016_j_ejcskn_2023_100004 crossref_primary_10_3390_cancers17061050 crossref_primary_10_1016_j_pdpdt_2021_102318 crossref_primary_10_3389_fonc_2024_1373263 crossref_primary_10_3390_cosmetics12010030 crossref_primary_10_62347_JOUT3260 crossref_primary_10_1016_j_rechem_2024_101715 crossref_primary_10_3390_ph15080985 crossref_primary_10_1016_j_pdpdt_2022_102752 crossref_primary_10_1016_j_pdpdt_2022_102783 crossref_primary_10_2147_CCID_S401206 |
Cites_doi | 10.1111/jdv.13228 10.1016/j.ijsu.2011.09.004 10.1111/jdv.14613 10.1159/000366548 10.1117/1.JBO.20.5.058001 10.1159/000353775 10.1111/j.1365-2133.2011.10209.x 10.1111/j.1365-2133.2012.11200.x 10.2340/00015555-2345 10.1111/j.1600-0781.2011.00611.x 10.1111/j.1365-2133.2008.08450.x 10.1111/bjd.13138 10.1111/jdv.12974 10.1684/ejd.2016.2882 10.1111/jdv.13076 |
ContentType | Journal Article |
Copyright | 2020 European Academy of Dermatology and Venereology 2020 European Academy of Dermatology and Venereology. |
Copyright_xml | – notice: 2020 European Academy of Dermatology and Venereology – notice: 2020 European Academy of Dermatology and Venereology. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1111/jdv.16208 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-3083 |
EndPage | 1735 |
ExternalDocumentID | 31955461 10_1111_jdv_16208 JDV16208 |
Genre | article Randomized Controlled Trial Journal Article |
GrantInformation_xml | – fundername: CHU of Limoges – fundername: Galderma |
GroupedDBID | --- --K .3N .GA .Y3 05W 0R~ 10A 1B1 1OB 1OC 1~5 29L 31~ 33P 36B 3SF 4.4 4G. 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AAHQN AAIPD AALRI AAMNL AANHP AANLZ AAONW AAQFI AAQXK AASGY AAXRX AAXUO AAYCA AAZKR ABCQN ABCUV ABEML ABJNI ABQWH ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADZMN AE3 AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFTJW AFWVQ AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG CO8 COF CS3 CYRXZ D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD ESX EX3 F00 F01 F04 F5P FDB FEDTE FGOYB FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 NF~ NQ- O66 O9- OIG OVD OZT P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K R2- RIG RIWAO RJQFR ROL RPZ RX1 SAMSI SEW SUPJJ TEORI UB1 UHS W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~WT AAYXX ACVFH ADCNI AEUPX AEYWJ AFPUW AGHNM AGQPQ AGYGG AIGII CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c3258-f2d0ac1ab9e404a5a69b099479859306a8ff92f57e5789c6fd5d82447733c57b3 |
IEDL.DBID | DR2 |
ISSN | 0926-9959 1468-3083 |
IngestDate | Fri Jul 11 16:12:49 EDT 2025 Mon Jul 21 05:59:28 EDT 2025 Tue Jul 01 04:12:05 EDT 2025 Thu Apr 24 22:54:19 EDT 2025 Wed Jan 22 16:32:41 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Language | English |
License | 2020 European Academy of Dermatology and Venereology. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3258-f2d0ac1ab9e404a5a69b099479859306a8ff92f57e5789c6fd5d82447733c57b3 |
Notes | The tubes of Metvixia were supplied by Galderma. The rest of this study was funded by the CHU of Limoges. None. Conflict of interest Funding source ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0003-1625-5203 |
PMID | 31955461 |
PQID | 2342362105 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_2342362105 pubmed_primary_31955461 crossref_primary_10_1111_jdv_16208 crossref_citationtrail_10_1111_jdv_16208 wiley_primary_10_1111_jdv_16208_JDV16208 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | August 2020 2020-08-00 2020-Aug 20200801 |
PublicationDateYYYYMMDD | 2020-08-01 |
PublicationDate_xml | – month: 08 year: 2020 text: August 2020 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of the European Academy of Dermatology and Venereology |
PublicationTitleAlternate | J Eur Acad Dermatol Venereol |
PublicationYear | 2020 |
References | 2015; 46 2015; 29 2017; 27 2015; 20 2013; 227 2016; 96 2013; 168 2014; 151 2008; 158 2014; 171 2011; 27 2018; 32 2011; 9 2011; 164 e_1_2_5_15_1 e_1_2_5_14_1 e_1_2_5_17_1 e_1_2_5_9_1 e_1_2_5_16_1 e_1_2_5_8_1 e_1_2_5_11_1 e_1_2_5_7_1 e_1_2_5_10_1 e_1_2_5_6_1 e_1_2_5_13_1 e_1_2_5_5_1 e_1_2_5_4_1 e_1_2_5_3_1 e_1_2_5_2_1 Fai D (e_1_2_5_12_1) 2014; 151 |
References_xml | – volume: 171 start-page: 1164 year: 2014 end-page: 1171 article-title: Daylight PDT with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional PDT in actinic keratosis treatment: a randomised controlled trial publication-title: Br J Dermatol – volume: 20 start-page: 58001 year: 2015 article-title: Comparison of three light doses in the photodynamic treatment of actinic keratosis using mathematical modeling publication-title: J Biomed Opt – volume: 9 start-page: 672 year: 2011 end-page: 677 article-title: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials publication-title: Int J Surg – volume: 32 start-page: 595 year: 2018 end-page: 600 article-title: Conventional vs. daylight photodynamic therapy for patients with actinic keratosis on face and scalp: 12‐month follow‐up results of a randomized, intra‐individual comparative analysis publication-title: J Eur Acad Dermatol Venereol – volume: 96 start-page: 712 year: 2016 end-page: 713 article-title: Long‐term outcome of daylight photodynamic therapy with amino‐5‐laevulinate nanoemulsion vs. methyl‐5‐aminolaevulinate for actinic keratoses publication-title: Acta Derm Venereol – volume: 158 start-page: 740 year: 2008 end-page: 746 article-title: Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single‐blinded study publication-title: Br J Dermatol – volume: 29 start-page: 2342 year: 2015 end-page: 2348 article-title: Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator‐blinded, controlled, phase III study throughout Europe publication-title: J Eur Acad Dermatol Venereol – volume: 151 start-page: 154 year: 2014 end-page: 159 article-title: Daylight photodynamic therapy with methyl aminolaevulinate in patients with actinic keratoses: a preliminary experience in southern Italy publication-title: G Ital Dermatol Venereol – volume: 227 start-page: 214 year: 2013 end-page: 225 article-title: Correlation between protoporphyrin IX fluorescence intensity, photobleaching, pain and clinical outcome of actinic keratosis treated by photodynamic therapy publication-title: Dermatology – volume: 29 start-page: 1718 year: 2015 end-page: 1723 article-title: Practical approach to the use of daylight photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: a European consensus publication-title: J Eur Acad Dermatol Venereol – volume: 27 start-page: 280 year: 2011 end-page: 285 article-title: Continuous ultra‐low‐intensity artificial daylight is not as effective as red LED light in photodynamic therapy of multiple actinic keratoses publication-title: Photodermatol Photoimmunol Photomed – volume: 164 start-page: 1083 year: 2011 end-page: 1090 article-title: A randomized, multicentre study of directed daylight exposure times of 1½ vs. 2½ h in daylight‐mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp publication-title: Br J Dermatol – volume: 46 start-page: 122 year: 2015 end-page: 128 article-title: Update on photodynamic treatment for actinic keratosis publication-title: Curr Probl Dermatol – volume: 168 start-page: 186 year: 2013 end-page: 191 article-title: Weather conditions and daylight‐mediated photodynamic therapy: protoporphyrin IX‐weighted daylight doses measured in six geographical locations publication-title: Br J Dermatol – volume: 29 start-page: 1926 year: 2015 end-page: 1932 article-title: Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: an intra‐patient, prospective, comparison study in Italy publication-title: J Eur Acad Dermatol Venereol – volume: 27 start-page: 89 year: 2017 end-page: 91 article-title: Long‐term efficacy and safety of daylight photodynamic therapy with methyl amninolevulinate for actinic keratosis of the face and scalp publication-title: Eur J Dermatol – ident: e_1_2_5_4_1 doi: 10.1111/jdv.13228 – ident: e_1_2_5_9_1 doi: 10.1016/j.ijsu.2011.09.004 – ident: e_1_2_5_15_1 doi: 10.1111/jdv.14613 – volume: 151 start-page: 154 year: 2014 ident: e_1_2_5_12_1 article-title: Daylight photodynamic therapy with methyl aminolaevulinate in patients with actinic keratoses: a preliminary experience in southern Italy publication-title: G Ital Dermatol Venereol – ident: e_1_2_5_17_1 doi: 10.1159/000366548 – ident: e_1_2_5_8_1 doi: 10.1117/1.JBO.20.5.058001 – ident: e_1_2_5_7_1 doi: 10.1159/000353775 – ident: e_1_2_5_11_1 doi: 10.1111/j.1365-2133.2011.10209.x – ident: e_1_2_5_5_1 doi: 10.1111/j.1365-2133.2012.11200.x – ident: e_1_2_5_16_1 doi: 10.2340/00015555-2345 – ident: e_1_2_5_10_1 doi: 10.1111/j.1600-0781.2011.00611.x – ident: e_1_2_5_2_1 doi: 10.1111/j.1365-2133.2008.08450.x – ident: e_1_2_5_3_1 doi: 10.1111/bjd.13138 – ident: e_1_2_5_6_1 doi: 10.1111/jdv.12974 – ident: e_1_2_5_13_1 doi: 10.1684/ejd.2016.2882 – ident: e_1_2_5_14_1 doi: 10.1111/jdv.13076 |
SSID | ssj0001158 |
Score | 2.359864 |
Snippet | Background
We know the efficacy of daylight phototherapy dynamic (DL‐PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared... We know the efficacy of daylight phototherapy dynamic (DL-PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1730 |
SubjectTerms | Aminolevulinic Acid - therapeutic use Humans Keratosis, Actinic - drug therapy Light Ointments - therapeutic use Photochemotherapy Photosensitizing Agents - therapeutic use Scalp Dermatoses - drug therapy Treatment Outcome |
Title | Daylight photodynamic therapy with methyl aminolevulinate cream is as effective as conventional photodynamic therapy with blue light in the treatment of actinic keratosis: a controlled randomized intra‐individual study |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjdv.16208 https://www.ncbi.nlm.nih.gov/pubmed/31955461 https://www.proquest.com/docview/2342362105 |
Volume | 34 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtUwELWqLio2vB_lpQGxYJOrXCdOYrpClKqqBAtEURdIkZ8iappUzb1Xald8Ah_YVb-EGedBy0uInaM4TqLMjM84Z44ZezHXhTSYF0SWexmlIk4jmfs80laKXM2VFiaofb7PdvfTvQNxsMa2xlqYXh9iWnAjzwjxmhxc6e6yk9vVbJ7xUOhLXC0CRB9-SEch0glRWPIsIk2tQVUosHjGK6_ORb8AzKt4NUw4OzfY5_FRe57J4Wy50DNz9pOK43--y012fQCi8Lq3nFtszTW32ca74Vf7HXa-jbk8Ze5w_KVdtLbfuR76eq1ToPVboO2nT2vAE01buxWR2hG6AgHRI6g6UB30fBEMqXRwmeL-l2F1vXTQ37tq6BRMdHhoPVApRoPXHJIedNtV3StQMFDua2cBZ1_bHlVn2Kxo6fri67dqKjuDoKd7l-3vvP34ZjcatoKITMJFEXluY2XQdKRL41QJlUmN2DbNJem1xZkqvJfci9xhBJIm81bYApFLnieJEblO7rH1pm3cAwY8czKzOBF4y1Ptc2UxBGHbFok2sRGb7OVoFKUZdNJpu466nPIluyrD19pkz6eux704yO86PRstq0TXpf8xqnHtsis5qS9mmHPjPe_3JjcNg5GR-INzfJpgOH8ev9zb_hQaD_-96yN2jdO6QSAyPmbri5Ole4LgaqGfBi_6DnIqJ4s |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIgEX3pTyNIgDl6yyTpzEiAuiVEtpe0At6gVFfoqoaVKR3ZXaEz-BH8iJX8KMnYSWlxA3R3GcRJkZz0y--YaQp1NVCA1xQWSYE1HK4zQSucsjZQTP5VQqrj3b524220-3DvjBCnkx1MIEfogx4Yaa4e01KjgmpM9quVlOphnDSt8L2NHbB1TvfpBHga_j7bBgWYSsWj2vkMfxDJee341-cTHPe6x-y9m8Sj4MDxuQJoeTxVxN9OlPPI7_-zbXyJXeF6Uvg_BcJyu2uUEu7vR_22-SrxsQzmPwTo8_tvPWhOb1NJRsnVBM4VLsQH1SUzjRtLVdIq4dvFeKvugRrToqOxogI2BV8eAsyv0vy6p6YWm4d9XgKToi4mnrKFZjNHDNIVJCt13VPaeS9qj72hoKG7Bpj6pTGFaYvf72-Us1Vp5RT6l7i-xvvt57NYv6bhCRThgvIsdMLDVIj7BpnEouM6HAvU1zgZRtcSYL5wRzPLdghITOnOGmAOclz5NE81wlt8lq0zb2DqEssyIzsBc4w1LlcmnACsHYFInSsebr5NkgFaXuqdKxY0ddjiGTWZb-a62TJ-PU48AP8rtJjwfRKkF78ZeMbGy76EqGBIwZhN1wz7Ugc-MyYBwRQjiFp_GS8-f1y62N935w99-nPiKXZns72-X2m92398hlhmkEj2u8T1bnnxb2Afhac_XQq9R3swMrpg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtUwELWqIlVseENbXgaxYJOrXCd2YlghLlelQIUQRV0gRX6KqGly1fuQ2hWfwAey4kuYcR60vITYOYrjJMrM-Ixz5piQR2OdSwN5QWSZl1HK4zSSmc8ibSXP1FhpboLa557Y2U93D_jBGnna18K0-hDDght6RojX6OAz6886uV2NxoJhoe-FVMQ5mvTk3Q_tKIA6IQxLJiIU1epkhQKNp7_0_GT0C8I8D1jDjDO9TD72z9oSTQ5Hy4UemdOfZBz_82WukEsdEqXPWtO5StZcfY1svOn-tV8nXyeQzGPqTmefmkVj263raVuwdUJxAZfi_tMnFYUTdVO5FbLaAbtSRKJHtJxTNactYQRiKh6c5bj_ZVhdLR1t713WeIoOfHjaeIq1GDVcc4iC0M28nD-hinac-8pZCtOvbY7KU2iWuHb97fOXcqg7o0FQ9wbZn754_3wn6vaCiEzCeB55ZmNlwHakS-NUcSWkBnCbZhIF22Khcu8l8zxzEIKkEd5ymwN0ybIkMTzTyU2yXje12ySUCSeFhZnAW5ZqnykLMQjaNk-0iQ3fIo97oyhMJ5SO-3VUxZAw2VURvtYWeTh0nbXqIL_r9KC3rAJ8F3_IqNo1y3nBUH5RQNIN97zVmtwwDIRGJBCO4WmC4fx5_GJ38iE0tv-9632y8XYyLV6_3Ht1m1xkuIYQSI13yPrieOnuAtBa6HvBob4DREMqXg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Daylight+photodynamic+therapy+with+methyl+aminolevulinate+cream+is+as+effective+as+conventional+photodynamic+therapy+with+blue+light+in+the+treatment+of+actinic+keratosis%3A+a+controlled+randomized+intra-individual+study&rft.jtitle=Journal+of+the+European+Academy+of+Dermatology+and+Venereology&rft.au=Assikar%2C+S&rft.au=Labrunie%2C+A&rft.au=Kerob%2C+D&rft.au=Couraud%2C+A&rft.date=2020-08-01&rft.issn=1468-3083&rft.eissn=1468-3083&rft.volume=34&rft.issue=8&rft.spage=1730&rft_id=info:doi/10.1111%2Fjdv.16208&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0926-9959&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0926-9959&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0926-9959&client=summon |